Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Atrium Therapeutics, Inc.NASDAQ: RNA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses of $36.76M in Q1 FY2026
Q1 FY2026 operating expenses was $36.76M.
Context
- Operating expenses amounted to 512.6% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 95.43M USD
- Year-over-year change
- —
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 95.43M | — |
Operating Expenses vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Operating Expenses figures are available to compare.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 18.62M |
| Cost of Revenue | 0 |
| Gross Profit | 18.62M |
| Gross Margin | 100.0% |
| Research & Development | 53.76M |
| Selling, General & Admin | 41.68M |
| Operating Expenses | 95.43M |
| Depreciation & Amortization | 323K |
| EBITDA | (76.5M) |
| EBITDA Margin | -410.9% |
| Operating Income | (76.81M) |
| Operating Margin | -412.6% |
| Interest Income | 0 |
| Interest Expense | 0 |
| Other Income / Expenses | (12K) |
| Income Before Tax | (76.83M) |
| Pre-Tax Margin | -412.6% |
| Income Tax Expense | (142K) |
| Net Income | (76.68M) |
| Net Margin | -411.9% |
| EPS (Basic) | (4.48) |
| EPS (Diluted) | (4.48) |
| Weighted Avg Shares | 17.11M |
| Weighted Avg Shares (Diluted) | 17.11M |
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.